From GlobeNewswire: 2025-05-12 16:00:00

MoonLake Immunotherapeutics reported its first quarter 2025 financial results, highlighting progress with the development of Nanobody® sonelokimab across various indications. They also announced completion of Phase 3 enrollment in HS, presented interim results for PPP, and ended the quarter with $480.1 million in cash. MoonLake secured a debt facility providing up to $500 million in funds. Important upcoming milestones include the initiation of new trials and top-line results for ongoing programs. The company is focused on inflammatory diseases with high unmet needs, such as hidradenitis suppurativa and psoriatic arthritis.

MoonLake Immunotherapeutics provided a detailed update on its financial results for the first quarter of 2025, showcasing its progress in clinical trials and the advancement of sonelokimab. The company emphasized key upcoming milestones, including the initiation of new trials and the release of top-line results for ongoing programs. MoonLake’s focus on inflammatory diseases with high unmet needs highlights their commitment to revolutionize outcomes for patients. With a strong financial position and ongoing trials in various indications, MoonLake is dedicated to creating next-level therapies for inflammatory diseases.



Read more at GlobeNewswire: MoonLake Immunotherapeutics Reports First Quarter 2025